CL2021001044A1 - Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria - Google Patents

Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria

Info

Publication number
CL2021001044A1
CL2021001044A1 CL2021001044A CL2021001044A CL2021001044A1 CL 2021001044 A1 CL2021001044 A1 CL 2021001044A1 CL 2021001044 A CL2021001044 A CL 2021001044A CL 2021001044 A CL2021001044 A CL 2021001044A CL 2021001044 A1 CL2021001044 A1 CL 2021001044A1
Authority
CL
Chile
Prior art keywords
plasma
wound healing
postoperative recovery
fractions
improve pain
Prior art date
Application number
CL2021001044A
Other languages
English (en)
Inventor
Ian Gallager
Marian Castro
Viktoria Kheifets
benson Lu
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CL2021001044A1 publication Critical patent/CL2021001044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen métodos y composiciones para mejorar la recuperación posoperatoria. Las composiciones utilizadas en los métodos incluyen plasma sanguíneo y fracciones de plasma sanguíneo derivadas de plasma sanguíneo con eficacia para tratar y/o prevenir afecciones asociadas con la recuperación posoperatoria.
CL2021001044A 2018-10-26 2021-04-23 Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria CL2021001044A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751448P 2018-10-26 2018-10-26
US201962842403P 2019-05-02 2019-05-02

Publications (1)

Publication Number Publication Date
CL2021001044A1 true CL2021001044A1 (es) 2021-11-26

Family

ID=70327508

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001044A CL2021001044A1 (es) 2018-10-26 2021-04-23 Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria

Country Status (15)

Country Link
US (5) US11103530B2 (es)
EP (1) EP3870190A4 (es)
JP (2) JP7504090B2 (es)
KR (2) KR20260004552A (es)
CN (2) CN113056275B (es)
AU (1) AU2019364271B2 (es)
BR (1) BR112021006743A2 (es)
CA (1) CA3115308A1 (es)
CL (1) CL2021001044A1 (es)
IL (1) IL282227B2 (es)
MX (1) MX2021004755A (es)
SG (1) SG11202103696XA (es)
TW (2) TWI885565B (es)
UA (1) UA128648C2 (es)
WO (1) WO2020086469A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103696XA (en) * 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
CN114746100B (zh) 2019-11-20 2024-10-25 万能溶剂有限公司 用于肝再生的血浆级分
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
WO2022150818A1 (en) * 2021-01-06 2022-07-14 Yuvan Research, Inc. Anti-aging compositions and uses thereof
AU2022275694A1 (en) * 2021-05-19 2023-11-16 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
WO2024258622A1 (en) * 2023-06-13 2024-12-19 Alkahest, Inc. Blood plasma fractions as a treatment for chemotherapy induced cognitive disorders

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4075197A (en) 1976-09-20 1978-02-21 Monsanto Company Serum albumin production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
JPS60154150A (ja) 1984-01-25 1985-08-13 Hitachi Ltd 電気泳動装置
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US5641483A (en) 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
EP1507543A4 (en) 2002-05-09 2006-07-26 Cambridgemed Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF WOOD WITH BLOOD PLASMA OR SERUM
JP2004051023A (ja) * 2002-07-22 2004-02-19 Toyota Motor Corp 車両の制御装置
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20040120937A1 (en) 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
AU2004224807A1 (en) 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
US20040254152A1 (en) 2003-04-17 2004-12-16 Monje Michelle L. Prevention of deficits in neurogenesis with anti-inflammatory agents
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
WO2005106492A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
CA2597431A1 (en) * 2005-02-11 2006-08-17 Cambridge Scientific Pty Ltd A method of producing an analgesic composition from plasma or serum and use in treating pain
KR100782333B1 (ko) * 2005-08-11 2007-12-06 메디제네스(주) 혈장 또는 혈청을 포함하는 신경손상 치료용 약학 조성물
US20070048387A1 (en) 2005-09-01 2007-03-01 Edwards Jeffrey D Tissue disruption treatment and composition for use thereof
WO2007059135A2 (en) 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
KR20070113876A (ko) * 2006-05-26 2007-11-29 메디제네스(주) 혈장성분을 함유하는 창상 치료용 약학 조성물
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
ES2333498B1 (es) 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
WO2009023814A2 (en) 2007-08-15 2009-02-19 University Of South Florida Hucbc treatment of amyloid associated disease
WO2009051660A2 (en) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Compounds for activating tgf-beta signaling
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
CN101888863B (zh) 2007-12-06 2012-11-28 旭化成医疗株式会社 血液处理用多孔中空纤维膜
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
AT516600B1 (de) 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
CN201453773U (zh) 2009-08-04 2010-05-12 侯涛 血浆专用注射器
WO2011094535A2 (en) 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US8313764B2 (en) 2010-06-22 2012-11-20 Stemnion, Inc. Wound healing device
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
CN104884611A (zh) 2012-02-13 2015-09-02 孔五一 Nprcp、pfdnc和它们的应用
IN2014MN02089A (es) 2012-03-20 2015-09-11 Einstein Coll Med
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9512052B2 (en) 2012-10-29 2016-12-06 China Petroleum & Chemical Corporation Adsorption desulfurization process for hydrocarbons and a reaction apparatus therefor
NZ720949A (en) 2013-12-09 2019-03-29 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
JP7134089B2 (ja) 2015-05-18 2022-09-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化に関連した障害を処置するための方法及び組成物
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
LT3484502T (lt) * 2016-08-18 2021-12-10 Alkahest, Inc. Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery

Also Published As

Publication number Publication date
KR20210068573A (ko) 2021-06-09
WO2020086469A1 (en) 2020-04-30
AU2019364271A1 (en) 2021-06-03
EP3870190A1 (en) 2021-09-01
US20200129550A1 (en) 2020-04-30
TWI885565B (zh) 2025-06-01
BR112021006743A2 (pt) 2021-07-13
IL282227B1 (en) 2024-04-01
US20230111752A1 (en) 2023-04-13
US11298377B2 (en) 2022-04-12
UA128648C2 (uk) 2024-09-18
MX2021004755A (es) 2021-06-08
US20230285455A1 (en) 2023-09-14
IL282227A (en) 2021-05-31
EP3870190A4 (en) 2022-09-07
SG11202103696XA (en) 2021-05-28
CN113056275B (zh) 2024-10-01
TW202029970A (zh) 2020-08-16
AU2019364271B2 (en) 2024-10-24
JP7785128B2 (ja) 2025-12-12
TWI819129B (zh) 2023-10-21
US11547724B2 (en) 2023-01-10
IL282227B2 (en) 2024-08-01
JP2022505915A (ja) 2022-01-14
US11103530B2 (en) 2021-08-31
CA3115308A1 (en) 2020-04-30
US20200129549A1 (en) 2020-04-30
KR20260004552A (ko) 2026-01-08
JP2024107305A (ja) 2024-08-08
CN113056275A (zh) 2021-06-29
TW202408565A (zh) 2024-03-01
JP7504090B2 (ja) 2024-06-21
CN119345230A (zh) 2025-01-24
US20210106616A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2021009673A (es) Moduladores de ror-gamma.
CY1121997T1 (el) Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CO2022000481A2 (es) Inhibidores de enzimas
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
MX2024007042A (es) Inhibidores de raf quinasa y metodos de uso de los mismos.
UY38352A (es) Inhibidores de integrina alfavbeta6
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX2022003396A (es) Uso de inhibidores de dkk-1 para tratar el cancer.